Serum Neurofilament Light Chain Levels May Be a Marker of Lower Motor Neuron Damage in Amyotrophic Lateral Sclerosis

被引:3
|
作者
Zhang, Linjing [1 ,2 ]
Ji, Tuo [1 ,3 ]
Wu, Chujun [1 ,4 ]
Zhang, Shuo [1 ,2 ]
Tang, Lu [1 ,2 ]
Zhang, Nan [1 ,2 ]
Liu, Xiangyi [1 ,2 ]
Fan, Dongsheng [1 ,2 ,5 ]
机构
[1] Peking Univ Third Hosp, Dept Neurol, Beijing, Peoples R China
[2] Beijing Municipal Key Lab Biomarker & Translat Re, Beijing, Peoples R China
[3] Zhengzhou Univ, Affiliated Hosp 1, Dept Neurol, Zhengzhou, Peoples R China
[4] Capital Med Univ, Beijing Tiantan Hosp, Dept Neurol, Beijing, Peoples R China
[5] Peking Univ, Minist Educ, Natl Hlth Commiss, Key Lab Neurosci, Beijing, Peoples R China
来源
FRONTIERS IN NEUROLOGY | 2022年 / 13卷
基金
中国国家自然科学基金;
关键词
NfL; amyotrophic lateral sclerosis; axonal degeneration; CMAPs; EMG; electromyogram; DIAGNOSIS; BIOMARKER; SURVIVAL; PROTEINS;
D O I
10.3389/fneur.2022.833507
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Objectives The aims of this study were to investigate whether serum neurofilament light chain (NfL) levels were correlated with the severity of the axonal degeneration of lower motor neurons (LMNs) in the early symptomatic phase of amyotrophic lateral sclerosis (ALS). Methods In this prospective study, the serum samples used for NfL measurement were obtained from 103 sporadic ALS outpatients within 2 years of disease duration. The severity of axonal degeneration was assessed by assessing the decrease in the compound muscle action potentials (CMAPs) within a 1-month interval from serum sampling. Results The NfL levels showed a significant positive correlation with the relative score as a proxy for the axonal damage of LMNs in patients with ALS (coefficient: 0.264, p = 0.009). Furthermore, this correlation became stronger (coefficient: 0.582, p = 0.037) when estimated only among patients with disease subtypes that involve only LMNs, that is, patients with flail arm or leg syndrome (FAS or FLS). The levels of NfL increased with the severity of axonal damage of LMNs (F = 6.694, P = 0.0001). Conclusions Serum NfL levels mirrored the severity of the axonal degeneration of LMNs, particularly in patients with signs of predominant LMN involvement. These results may have a profound effect on the selection of patients and the monitoring of treatment efficacy in future disease-modifying clinical trials.
引用
收藏
页数:8
相关论文
共 50 条
  • [21] Serum Neurofilament Light Chain Levels are Associated with Lower Thalamic Perfusion in Multiple Sclerosis
    Jakimovski, Dejan
    Bergsland, Niels
    Dwyer, Michael G.
    Ramasamy, Deepa P.
    Ramanathan, Murali
    Weinstock-Guttman, Bianca
    Zivadinov, Robert
    DIAGNOSTICS, 2020, 10 (09)
  • [22] Diagnostic and Prognostic Biomarkers in Amyotrophic Lateral Sclerosis Neurofilament Light Chain Levels in Definite Subtypes of Disease
    Gaiani, Alessandra
    Martinelli, Ilaria
    Bello, Luca
    Querin, Giorgia
    Puthenparampil, Marco
    Ruggero, Susanna
    Toffanin, Elisabetta
    Cagnin, Annachiara
    Briani, Chiara
    Pegoraro, Elena
    Soraru, Gianni
    JAMA NEUROLOGY, 2017, 74 (05) : 525 - 532
  • [23] Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
    Yadav, Rimjhim
    Saini, Ayushi
    Choudhary, Jyoti
    Sardana, Silki
    Ohlan, Anil
    Singh, Kuldeep
    Singh, Surinder P.
    ENERGY STORAGE, 2023, 5 (08)
  • [24] Neurofilament light chain in drug development for amyotrophic lateral sclerosis: a critical appraisal
    Benatar, Michael
    Wuu, Joanne
    Turner, Martin R.
    BRAIN, 2023, 146 (07) : 2711 - 2716
  • [25] Biomarker Qualification for Neurofilament Light Chain in Amyotrophic Lateral Sclerosis: Theory and Practice
    Benatar, Michael
    Ostrow, Lyle W.
    Lewcock, Joseph W.
    Bennett, Frank
    Shefner, Jeremy
    Bowser, Robert
    Larkin, Paul
    Bruijn, Lucie
    Wuu, Joanne
    ANNALS OF NEUROLOGY, 2024, 95 (02) : 211 - 216
  • [26] Motor neuron protection in amyotrophic lateral sclerosis
    Carmichael, G
    LANCET NEUROLOGY, 2005, 4 (02): : 81 - 82
  • [27] MOTOR NEURON DISEASES AND AMYOTROPHIC LATERAL SCLEROSIS
    ROWLAND, LP
    TRENDS IN NEUROSCIENCES, 1984, 7 (04) : 110 - 112
  • [28] Serum neurofilament light chain levels as multiple sclerosis biomarker
    Abd-ElHady, Mohamed E.
    Hashish, Ehab
    Yassine, Imane
    Anani, Maha
    Negm, Mohamed
    PROGRESS IN NEUROLOGY AND PSYCHIATRY, 2024, 28 (02) : 28 - 32
  • [29] Lower motor neuron involvement examined by quantitative electromyography in amyotrophic lateral sclerosis
    Krarup, Christian
    CLINICAL NEUROPHYSIOLOGY, 2011, 122 (02) : 414 - 422
  • [30] Upper and lower motor neuron function and muscle weakness in amyotrophic lateral sclerosis
    KentBraun, JA
    Walker, CH
    Weiner, MW
    Miller, RG
    NEUROLOGY, 1996, 46 (02) : 64005 - 64005